<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03628365</url>
  </required_header>
  <id_info>
    <org_study_id>CER-2018-00556</org_study_id>
    <nct_id>NCT03628365</nct_id>
  </id_info>
  <brief_title>Can Beta-Hydroxy-beta-Methylbutyrate Supplementation Counteract Muscle Catabolism in Critically Ill Patients?</brief_title>
  <acronym>HMB-ICU-CH</acronym>
  <official_title>Can Beta-Hydroxy-beta-Methylbutyrate (HMB) Supplementation Counteract Muscle Catabolism in Critically Ill Patients? A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mette M Berger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas A&amp;M University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rapid decline of muscle mass and function in mechanically ventilated critically ill
      patients is associated with prolonged length of mechanical ventilation, prolonged intensive
      care (ICU) and hospital stay, increased ICU and hospital mortality, and prolonged impairment
      in physical function and quality of life. High protein feeding only partially attenuates the
      muscle loss. The aim is to study the impact of HMB (3 g/day) on the muscle mass of the
      critically ill patients from day 4 of their admission to maximum 30 days, but at least for 10
      days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The rapid decline of muscle mass and function in mechanically ventilated critically ill
      patients is associated with poor outcome, and limitations of functional recovery. High
      protein feeding only partially attenuates the muscle loss. The aim is to study the impact of
      HMB (3 g/day) on the muscle mass of the critically ill patients from day 4 of their admission
      to maximum 30 days, but at least for 10 days. The study is testing a nutrition complement
      (HMB) that is included in feeding products registered for medical nutrition by Swiss Federal
      Authorities, but who do not provide sufficient protein quantities.

      On days 4 and 15 after ICU admission, specific investigations will include: Ultrasound
      measurement of the muscle quadriceps femoris (CSA), bioimpedance analysis (BIA) of body
      composition, protein synthesis and catabolism using amino acid tracers. On D30 and D60:
      telephone contact to assess global health and mobility (SF-12).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Actual">January 6, 2020</completion_date>
  <primary_completion_date type="Actual">January 6, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, double blind, controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomisation controlled by the Hospital Pharmacy Intervention product masked by the Hospital Pharmacy</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle mass of the thigh</measure>
    <time_frame>Change between Day 4 and Day 15</time_frame>
    <description>Ultrasound cross sectional area of the thigh, to quantify muscle loss</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Change between Day 4 and Day 15</time_frame>
    <description>Bioelectrical impedance analysis (BIA): calculation of body compartments, lean body mass, and phase angle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein synthesis and breakdown</measure>
    <time_frame>Change between Day 4 and Day 15</time_frame>
    <description>Multiple Amino acid tracer study: to detect chnges in protein metabolism between study start on day 4 and day 14 (i.e. after 10 days of intervention (HMB or placebo))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength (global and handgrip)</measure>
    <time_frame>Measurements on Days 4, 15, and 30</time_frame>
    <description>Medical Research Council muscle score (MRC) to assess upper and lower limb strength, and handgrip strength (not always feasible in ICU patients) and determine magnitude of strength loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Health and Mobility</measure>
    <time_frame>on days 30 and 60</time_frame>
    <description>Short Form 12 (SF-12) questionnaire to assess global health and mobility: range 12 to 56 points, the upper limit reflecting return to normal activity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Critical Illness</condition>
  <condition>Muscle Weakness</condition>
  <arm_group>
    <arm_group_label>HMB (beta-hydroxy beta-methylbutyrate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HMB, 1.5 g b.i.d., from day 4 to day 30 after ICU admission</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin, 1.5 g b.i.d., from day 4 to day 30 after ICU admission</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HMB (beta-hydroxy beta-methylbutyrate)</intervention_name>
    <description>1.5 g, b.i.d., by the enteral route, from Day 4 to Day 30 (minimum 10 days)</description>
    <arm_group_label>HMB (beta-hydroxy beta-methylbutyrate)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  likely length of stay &gt;5 days

          -  on mechanical ventilation

          -  likely survival &gt;7 days

          -  full treatment

          -  functional gastro-intestinal tract

          -  presence of a central venous catheter

        Exclusion Criteria:

          -  absence of consent

          -  less than 18 years patients

          -  gastro-intestinal dysfunction

          -  major burns &gt;20% body surface

          -  admission for cardio-respiratory arrest or brain injury

          -  pregnancy or lactation

          -  diabetes mellitus (I and II)

          -  statin treatment

          -  patient on parenteral nutrition

          -  absence of central venous line

          -  participation in another interventional trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Lausanne Hospitals</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Deutz NE, Matheson EM, Matarese LE, Luo M, Baggs GE, Nelson JL, Hegazi RA, Tappenden KA, Ziegler TR; NOURISH Study Group. Readmission and mortality in malnourished, older, hospitalized adults treated with a specialized oral nutritional supplement: A randomized clinical trial. Clin Nutr. 2016 Feb;35(1):18-26. doi: 10.1016/j.clnu.2015.12.010. Epub 2016 Jan 18.</citation>
    <PMID>26797412</PMID>
  </results_reference>
  <results_reference>
    <citation>Deutz NE, Pereira SL, Hays NP, Oliver JS, Edens NK, Evans CM, Wolfe RR. Effect of β-hydroxy-β-methylbutyrate (HMB) on lean body mass during 10 days of bed rest in older adults. Clin Nutr. 2013 Oct;32(5):704-12. doi: 10.1016/j.clnu.2013.02.011. Epub 2013 Mar 4.</citation>
    <PMID>23514626</PMID>
  </results_reference>
  <results_reference>
    <citation>Engelen MPKJ, Deutz NEP. Is β-hydroxy β-methylbutyrate an effective anabolic agent to improve outcome in older diseased populations? Curr Opin Clin Nutr Metab Care. 2018 May;21(3):207-213. doi: 10.1097/MCO.0000000000000459. Review.</citation>
    <PMID>29406417</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Mette M Berger</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Body composition</keyword>
  <keyword>muscle mass</keyword>
  <keyword>protein metabolism</keyword>
  <keyword>enteral nutrition</keyword>
  <keyword>ICU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

